Pharmaceutical

AstraZeneca buys Chinese CAR-T biotech Gracell in a $1.2bn deal

The deal is worth approximately $1.2bn in combined upfront and potential contingent value payments and is expected to close in Q1 2024.

Dec 28, 2023 - 18:00
AstraZeneca buys Chinese CAR-T biotech Gracell in a $1.2bn deal
The deal is worth approximately $1.2bn in combined upfront and potential contingent value payments and is expected to close in Q1 2024.
Read the original article

Tags:

Previous Article

ARTBIO divulges plans for proprietary isotope manufacturing technology

Next Article

Bristol Myers Squibb agrees to acquire RPT company RayzeBio for $4.1bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: House moves to limit so-called gain-of-function research

STAT+: House moves to limit so-called gain-of-function ...

Nov 15, 2023

Zerva acquires Acer Therapeutics to bolster rare disease portfolio

Zerva acquires Acer Therapeutics to bolster rare diseas...

Sep 1, 2023

Who’s hiring who? Hiring activity in the Asia-Pacific pharma industry increased by 2% in Q1 2023

Who’s hiring who? Hiring activity in the Asia-Pacific p...

Jun 9, 2023